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A core network of genes maintaining pluripotency has been at least partially defined. How the ge-
netic switch is flipped to differentiation is the subject of a new study that reveals some unexpected
players.The past decade has witnessed immense
progress in our understanding of how
embryonic stem (ES) cell pluripotency
and self-renewal are controlled at the
molecular level. Despite these advances,
vanishingly little is known about the initial
events that dissolve this ground state
circuitry and allow differentiation to unfurl.
In this issue of Cell, Betschinger et al.
tackle this conundrum and identify a hith-
erto uncharacterized sentinel at the exit
door to differentiation (Betschinger et al.,
2013).
Pluripotent mouse ES cells are easily
maintained in medium supplemented
with two small molecule inhibitors (2i
culture). This formulation ensures uniform
and robust expression of signature
marker genes, e.g., Oct4, Sox2, and
Nanog, resulting in so-called ‘‘naive’’ plu-
ripotency (Wray et al., 2010). Betschinger
et al. exploited the simple 2i platform to
perform a high-throughput siRNA screen
for genes whose loss safeguards pluri-
potency in the face of differentiation con-
ditions—specifically, 2i withdrawal. Their
screen was successful, as several genes
encoding components of the FGF/
MAPK- and Wnt/GSK3-signaling path-
ways—the targets of 2i inhibition—were
recovered. It also yielded a few surprises.
Among the novel hits was the tumor
suppressor Folliculin (Flcn). Flcn encodes
an evolutionarily conserved cytoplasmic
protein with no recognizable motifs and
no previously described role in ES cell
biology. FLCN was first identified as the
gene mutated in Birt-Hogg-Dube´ (BHD)
syndrome, which is characterized by
numerous benign hair follicle tumors, for
which Flcn is named (Nickerson et al.,2002). Flcn likely piqued the author’s in-
terest because loss-of-function studies
in mouse previously showed that Flcn
null embryos die soon after implantation
with a disorganized epiblast (Hasumi
et al., 2009). One possible explanation
for this phenotype is that epiblast cells
fail to disengage the pluripotency pro-
gram and are effectively stuck develop-
mentally. This is supported by the au-
thor’s observation that Flcn knockdown
ES cells do not differentiate even when
confronted with a potent trio of recombi-
nant growth factors that normally induces
robust mesendoderm differentiation. Flcn
is therefore required for efficient exit from
naive pluripotency (Figure 1).
Although not found in their siRNA
screen, the authors also investigated two
previously identified Flcn-interacting pro-
teins, Fnip1 and -2 (Baba et al., 2006).
Biochemical experiments confirm the
existence of Flcn-Fnip1 complexes in ES
cells, and Fnip1/2 knockdown cells with-
stand differentiation conditions compara-
ble to loss of Flcn. Fnip-Flcn1 provides an
intriguing mechanistic link to the mTOR
pathway. mTOR is a multifunctional
kinase that serves as a nexus for diverse
cellular inputs, from nutrient deprivation
to growth factor and hormone signals
(Laplante and Sabatini, 2012). Fnip1 was
previously shown to bind AMPK, which
phosphorylates Flcn and Fnip1 and also
Tsc2, a negative regulator of mTOR
(Baba et al., 2006). Tsc2 is among the
top hits from the siRNA screen, indicating
that increased mTOR signaling opposes
exit from the ground state.
What are the downstream targets of
Flcn? One clue emerged from studies ofCellthe bHLH transcription factor TFE3. In a
BHD cancer cell line, TFE3 is constitu-
tively nuclear (Hong et al., 2010). In mouse
ES cells, Tfe3 is distributed heteroge-
neously in both the nucleus and cyto-
plasm. Similar to BHD cells, knockdown
of Flcn results in nuclear Tfe3. During dif-
ferentiation, however, Tfe3 is restricted
exclusively to the cytoplasm of wild-type
ES cells (Figure 1) but remains mostly
nuclear in differentiation-resistant clones
depleted of Flcn, Fnip1/2, or Tsc2. Inter-
estingly, a similar pattern of Tfe3 sub-
cellular distribution was observed in vivo.
In blastocyst-stage mouse embryos, Tfe3
is observed in the nucleus of pluripotent
inner cell mass cells. Soon after implanta-
tion, Tfe3 protein is exclusively cyto-
plasmic in the epiblast epithelium—the
seat of primed pluripotency just prior to
gastrulation. The author’s in vitro results
predict that nuclear Tfe3 will persist in
Flcn/ embryos.
Tfe3 is firmly established as the key
functional mediator of input from Flcn-
Fnip1/2 and Tsc2/mTOR by epistasis
studies demonstrating that knockdown
of Tfe3 restores the ability of clones
depleted of Flcn, Fnip1/2, or Tsc2 to
differentiate. The authors further show
that Tfe3 is indeed sufficient to block
exit from naive pluripotency. An engi-
neered form of Tfe3 that allows for induc-
ible nuclear translocation permits normal
differentiation when left cytoplasmic but,
when forced into the nucleus, precludes
differentiation.
These initial findings raise a number of
interesting questions. First, how is resto-
ration of FGF and Wnt signaling at the
onset of differentiation relayed to Flcn,153, April 11, 2013 ª2013 Elsevier Inc. 281
Figure 1. The Flcn-Tfe3 Pathway and Exit from Ground-State Pluripotency
In medium supplemented with 2i (MEKi and GSK-3bi), the expression of the pluripotency gene Esrrb is directly regulated by Nanog. Tfe3 is found in both the
cytoplasm and in the nucleus, where it binds Esrrb and supports expression of ground-state factors. When 2i is withdrawn, mouse ES cells exit the pluripotent
ground state and begin commitment. Exit is accompanied by decreasing Esrrb expression, resulting from a decline in Nanog levels, inhibition by Tcf3, and nuclear
exclusion of Tfe3. Flcn-Fnip1/2 and Tsc1/2 are necessary to restrict Tfe3 to the cytoplasm. Tsc1/2 keep mTOR activity low during ES cell exit from ground state.
After exit, AMPK may positively regulate Flcn to constrain Tfe3 to the cytoplasm.resulting in Tfe3 nuclear exclusion? Tsc2
is the likely sensor, given that it integrates
inputs from both the FGF- and Wnt-
signaling pathways (Laplante and Saba-
tini, 2012). It is, however, unknown
whether Flcn is directly phosphorylated
by mTOR, which would suggest a linear
Tsc2/mTOR/Flcn pathway, or other ki-
nases in ES cells, or even whether such
phosphorylation is significant functionally.
Second, is Tfe3 actively exported from the
nucleus at the onset of differentiation, or,
alternatively, is its nuclear import simply
inhibited? In this regard, it will be inter-
esting to determine the Tfe3 interactome,
both when Tfe3 is forced to be predomi-
nantly nuclear, such as in Flcn-shRNA
knockdown ES cells, and during dif-
ferentiation, when Tfe3 is cytoplasmic.
Similarly, Flcn itself is a mysterious pro-
tein, and identifying interacting partners
alongside structure-function studies will
further elaborate its role in driving exit282 Cell 153, April 11, 2013 ª2013 Elsevier Infrom pluripotency. It remains possible
that Flcn itself sequesters Tfe3 in the
cytoplasm.
Astonishingly, cells with constitutively
nuclear Tfe3 grow and remain pluripotent
without 2i! This unprecedented finding
emphasizes how powerfully Tfe3 impacts
the transcriptional network underlying ES
cell self-renewal and immediately invites
questions about the identity of Tfe3 tran-
scriptional targets. Chromatin immuno-
precipitation-sequencing studies reveal
1,500 genes that are cobound by Tfe3,
Oct4/Sox2/Nanog, and the Wnt/GSK3
signaling effector Tcf3. Among these
co-occupied loci were well-established
regulators of pluripotency, including
the nuclear hormone receptor Essrb
(Figure 1). Essrb is a crucial direct target
of Wnt/GSK3 and Nanog in the mainte-
nance of ES cell renewal (Festuccia
et al., 2012; Martello et al., 2012). Essrb
knockdown was, however, only able toc.partially overcome the differentiation
barrier erected by nuclear Tfe3, indicating
that other key Tfe3 targets lurk among the
author’s gene lists. In fact, Tfe3 effectively
trumps the ability of Essrb or Nanog to
individually sustain ES cell self-renewal,
as overexpression of either factor still re-
quires tailored medium formulations (Fes-
tuccia et al., 2012; Martello et al., 2012;
Ying et al., 2008).
In sum, the groundbreaking results of
Betschinger et al. lift Tfe3 out of relative
obscurity and will likely grab the attention
of diverse scientists, emboldening the
pursuit of a deeper understanding of the
Flcn-Tfe3 gatekeeper module with fervor
equal to the study of the previously
anointed ‘‘core’’ pluripotency factors.REFERENCES
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In the liver, the hepatocyte mass is kept stable through a tight balance between hepatocyte
death and proliferation that is frequently lost upon acute or chronic liver injury. Wuestefeld et al.
(2013) now identify a potentially druggable target that enhances hepatocyte proliferation and
promotes liver regeneration, thereby preventing liver failure.Hepatocytes can proliferate extensively,
which is critical for liver homeostasis
and, even more so, liver regeneration. In
severe liver diseases, however, excessive
hepatocyte death may not be sufficiently
compensated by normal hepatocyte
proliferation, leading to loss of liver func-
tion and ultimately multiorgan failure.
Thus, strategies for identifying druggable
targets that could enhance liver regenera-
tion are of great therapeutic value. Toward
this aim, Wuestefeld et al. (2013) per-
formed anRNA interference (RNAi) screen
in mouse models of subacute and chronic
liver injury knocking down 301 putative
tumor suppressor genes previously iden-
tified in human hepatocellular carcinomas
(Zender et al., 2008). They identify a gene
whose suppression leads to a robust
increase in the proliferative capacity of
hepatocytes, representing a potentially
valuable target for future treatments.In both liver disease models the top hit
is mitogen-activated protein kinase
(MKK) 4. Of the seven currently known
MKKs, MKK4 (also known as SEK1) and
MKK7 (SEK2) are activators of c-Jun
N-terminal kinase (JNK) signaling, which
regulates essential cell functions such as
proliferation and survival (Haeusgen
et al., 2011). Mice deficient in MKK4 and
MKK7 exhibit defects in liver development
due to death and cell-cycle arrest of em-
bryonic liver progenitors (Nishina et al.,
1999; Wada et al., 2004). By dissecting
the function of MKK4 and MKK7 in hepa-
tocytes of adult mice, Wuestefeld et al.
shed new light on the regulation and func-
tion of JNK signaling in postnatal liver
regeneration and unexpectedly suggest
inhibition of MKK4 as a strategy for
improving or restoring it.
Inhibition of MKK4 has multiple benefi-
cial effects. First, it significantly acceler-ates hepatocyte proliferation, both in the
fumarylacetoacetate hydrolase-deficient
mouse model of subacute liver failure
and after chronic liver injury with carbon
tetrachloride. Second, MKK4-deficient
hepatocytes are protected from Fas-
mediated apoptosis. Finally, MKK4 defi-
ciency also decreases the severity of liver
fibrosis. This last finding underscores the
importance of hepatocyte cell cycle arrest
and death as triggers of liver cirrhosis.
At the molecular level, MKK4 knock-
down causes activation of JNK signaling.
This finding is unexpected, considering
that MKK4 is a JNK activator. As the un-
derlying mechanism the authors identify
compensatory activation of MKK7 using
a combinatorial gene knockdown strat-
egy: Concurrent knockdown of MKK7 in
MKK4-deficient hepatocytes abolishes
the phenotype of accelerated prolifera-
tion. Further investigations reveal that153, April 11, 2013 ª2013 Elsevier Inc. 283
